Double blind comparative study on cefetamet pivoxil vs cefixime in chronic respiratory tract infections

Fumio Matsumoto; Takeo Imai; Akira Saito; Yohmei Hiraga; Mitsuhide Ohmichi; Kazuo Takebe; Kenichi Imamura; Kotaro Oizumi; Akira Watanabe; Hiroyuki Nakai; Junichi Saito; Kazunao Niizuma; Kikuo Ohnuma; Masataka Katsu; Akira Ohishi; Shinji Okui; Shoichiro Irimajiri; Yasuo Matsuoka; Seiji Mita; Osamu Sakai; Jingoro Shimada; Kohya Shiba; Shinichi Tanimoto; Kazuo Ohara; Hideo Ikemoto; Takeshi Mori; Tsukasa Ebe; Hiroyuki Kobayashi; Hiroaki Takeda; Hiroshi Oshitani; Izumi Hayashi; Koichiro Nakata; Masayuki Noguchi; Masaru Koyama; Harumi Shishido; Hideaki Nagai; Shigeki Odagiri; Kaneo Suzuki; Hiroshi Takahashi; Kenichi Takahashi; Masaaki Arakawa; Koichi Wada; Takashi Kawashima; Toshiyuki Yamamoto; Kanzo Suzuki; Toru Matsuura; Nobuhiro Narita; Masayoshi Sawaki; Keiichi Mikasa; Fumio Miki; Rinzo Soejima; Niro Okimoto; Takao Sasaki; Yukio Matsumoto; Yuji Sugimoto; Michio Yamakido; Shinichi Ishioka; Yoshiro Sawae; Yukio Kumagai; Kohei Hara; Keizo Matsumoto; Hirofumi Tanaka; Atsushi Shinoda; Yoshinari Kitahara; Atsushi Saito; Yoshiteru Shigeno; Yuei Irabu; Hiroshi Fukuhara; Masakiyo Ishihara; Koichi Deguchi; Nobuya Ogawa; Jingoro Shimada

doi:10.11250/chemotherapy1953.39.844

Double blind comparative study on cefetamet pivoxil vs cefixime in chronic respiratory tract infections

Fumio Matsumoto, Takeo Imai, Akira Saito, Yohmei Hiraga, Mitsuhide Ohmichi, Kazuo Takebe, Kenichi Imamura, Kotaro Oizumi, Akira Watanabe, Hiroyuki Nakai, Junichi Saito, Kazunao Niizuma, Kikuo Ohnuma, Masataka Katsu, Akira Ohishi, Shinji Okui, Shoichiro Irimajiri, Yasuo Matsuoka, Seiji Mita, Osamu SakaiJingoro Shimada, Kohya Shiba, Shinichi Tanimoto, Kazuo Ohara, Hideo Ikemoto, Takeshi Mori, Tsukasa Ebe, Hiroyuki Kobayashi, Hiroaki Takeda, Hiroshi Oshitani, Izumi Hayashi, Koichiro Nakata, Masayuki Noguchi, Masaru Koyama, Harumi Shishido, Hideaki Nagai, Shigeki Odagiri, Kaneo Suzuki, Hiroshi Takahashi, Kenichi Takahashi, Masaaki Arakawa, Koichi Wada, Takashi Kawashima, Toshiyuki Yamamoto, Kanzo Suzuki, Toru Matsuura, Nobuhiro Narita, Masayoshi Sawaki, Keiichi Mikasa, Fumio Miki, Rinzo Soejima, Niro Okimoto, Takao Sasaki, Yukio Matsumoto, Yuji Sugimoto, Michio Yamakido, Shinichi Ishioka, Yoshiro Sawae, Yukio Kumagai, Kohei Hara, Keizo Matsumoto, Hirofumi Tanaka, Atsushi Shinoda, Yoshinari Kitahara, Atsushi Saito, Yoshiteru Shigeno, Yuei Irabu, Hiroshi Fukuhara, Masakiyo Ishihara, Koichi Deguchi, Nobuya Ogawa, Jingoro Shimada

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

We carried out a double-blind comparative study on cefetamet pivoxil (CEMT-PI) to evaluate its clinical efficacy and safety in the treatment of bacterial respiratory tract infections (RTI) namely, infectious exacerbation of chronic respiratory disease, using cefixime (CFIX) as the active reference drug. Either CEMT-PI at 1,000 mg/day or CFIX at 400 mg/day was given orally in two divided doses for 14 days in principle. The results obtained were as follows. (1) The efficacy rates were 83.3 % (55/66) in the CEMT-PI group and 72.7 % (48/66) in the CFIX group as judged by the committee, and 81.8% (54/66) in the CEMT-PI group, and 69.7% (46/66) in the CFIX group as judged by the doctor in charge. No significant differences were observed in efficacy rates between the two treatment groups. (2) The rates of eradication of the causative organisms were 82.4 % (28/34) in the CEMT-PI group and 71.9 % (23/32) in the CFIX group as judged by the committee, with no significant difference between the two treatment groups. (3) The incidence of side effects was 9.3 % (7/75) in the CEMT-PI group and 3.9 % (3/77) in the CFIX group, and that of abnormal laboratory findings was 15.1 % (11/73) in the CEMT-PI group and 14.7% (11/75) in the CFIX group as judged by the committee. No significant differences were observed in the incidences of side effects and of abnormal laboratory findings. From our results we conclude that CEMT-PI is highly effective and useful in the treatment of bacterial respiratory tract infections and is equivalent to CFIX.

Original language	English
Pages (from-to)	844-863
Number of pages	20
Journal	Chemotherapy
Volume	39
Issue number	9
DOIs	https://doi.org/10.11250/chemotherapy1953.39.844
Publication status	Published - 1991
Externally published	Yes

Keywords

cefetamet pivoxil
cefixime

ASJC Scopus subject areas

Pharmacology (medical)
Infectious Diseases
Pharmacology
Drug Discovery
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.11250/chemotherapy1953.39.844

Cite this

Matsumoto, F., Imai, T., Saito, A., Hiraga, Y., Ohmichi, M., Takebe, K., Imamura, K., Oizumi, K., Watanabe, A., Nakai, H., Saito, J., Niizuma, K., Ohnuma, K., Katsu, M., Ohishi, A., Okui, S., Irimajiri, S., Matsuoka, Y., Mita, S., ... Shimada, J. (1991). Double blind comparative study on cefetamet pivoxil vs cefixime in chronic respiratory tract infections. Chemotherapy, 39(9), 844-863. https://doi.org/10.11250/chemotherapy1953.39.844

Matsumoto, F, Imai, T, Saito, A, Hiraga, Y, Ohmichi, M, Takebe, K, Imamura, K, Oizumi, K, Watanabe, A, Nakai, H, Saito, J, Niizuma, K, Ohnuma, K, Katsu, M, Ohishi, A, Okui, S, Irimajiri, S, Matsuoka, Y, Mita, S, Sakai, O, Shimada, J, Shiba, K, Tanimoto, S, Ohara, K, Ikemoto, H, Mori, T, Ebe, T, Kobayashi, H, Takeda, H, Oshitani, H, Hayashi, I, Nakata, K, Noguchi, M, Koyama, M, Shishido, H, Nagai, H, Odagiri, S, Suzuki, K, Takahashi, H, Takahashi, K, Arakawa, M, Wada, K, Kawashima, T, Yamamoto, T, Suzuki, K, Matsuura, T, Narita, N, Sawaki, M, Mikasa, K, Miki, F, Soejima, R, Okimoto, N, Sasaki, T, Matsumoto, Y, Sugimoto, Y, Yamakido, M, Ishioka, S, Sawae, Y, Kumagai, Y, Hara, K, Matsumoto, K, Tanaka, H, Shinoda, A, Kitahara, Y, Saito, A, Shigeno, Y, Irabu, Y, Fukuhara, H, Ishihara, M, Deguchi, K, Ogawa, N & Shimada, J 1991, 'Double blind comparative study on cefetamet pivoxil vs cefixime in chronic respiratory tract infections', Chemotherapy, vol. 39, no. 9, pp. 844-863. https://doi.org/10.11250/chemotherapy1953.39.844

@article{c27db7a16cda45abb13614cddebf9827,

title = "Double blind comparative study on cefetamet pivoxil vs cefixime in chronic respiratory tract infections",

abstract = "We carried out a double-blind comparative study on cefetamet pivoxil (CEMT-PI) to evaluate its clinical efficacy and safety in the treatment of bacterial respiratory tract infections (RTI) namely, infectious exacerbation of chronic respiratory disease, using cefixime (CFIX) as the active reference drug. Either CEMT-PI at 1,000 mg/day or CFIX at 400 mg/day was given orally in two divided doses for 14 days in principle. The results obtained were as follows. (1) The efficacy rates were 83.3 % (55/66) in the CEMT-PI group and 72.7 % (48/66) in the CFIX group as judged by the committee, and 81.8% (54/66) in the CEMT-PI group, and 69.7% (46/66) in the CFIX group as judged by the doctor in charge. No significant differences were observed in efficacy rates between the two treatment groups. (2) The rates of eradication of the causative organisms were 82.4 % (28/34) in the CEMT-PI group and 71.9 % (23/32) in the CFIX group as judged by the committee, with no significant difference between the two treatment groups. (3) The incidence of side effects was 9.3 % (7/75) in the CEMT-PI group and 3.9 % (3/77) in the CFIX group, and that of abnormal laboratory findings was 15.1 % (11/73) in the CEMT-PI group and 14.7% (11/75) in the CFIX group as judged by the committee. No significant differences were observed in the incidences of side effects and of abnormal laboratory findings. From our results we conclude that CEMT-PI is highly effective and useful in the treatment of bacterial respiratory tract infections and is equivalent to CFIX.",

keywords = "cefetamet pivoxil, cefixime",

author = "Fumio Matsumoto and Takeo Imai and Akira Saito and Yohmei Hiraga and Mitsuhide Ohmichi and Kazuo Takebe and Kenichi Imamura and Kotaro Oizumi and Akira Watanabe and Hiroyuki Nakai and Junichi Saito and Kazunao Niizuma and Kikuo Ohnuma and Masataka Katsu and Akira Ohishi and Shinji Okui and Shoichiro Irimajiri and Yasuo Matsuoka and Seiji Mita and Osamu Sakai and Jingoro Shimada and Kohya Shiba and Shinichi Tanimoto and Kazuo Ohara and Hideo Ikemoto and Takeshi Mori and Tsukasa Ebe and Hiroyuki Kobayashi and Hiroaki Takeda and Hiroshi Oshitani and Izumi Hayashi and Koichiro Nakata and Masayuki Noguchi and Masaru Koyama and Harumi Shishido and Hideaki Nagai and Shigeki Odagiri and Kaneo Suzuki and Hiroshi Takahashi and Kenichi Takahashi and Masaaki Arakawa and Koichi Wada and Takashi Kawashima and Toshiyuki Yamamoto and Kanzo Suzuki and Toru Matsuura and Nobuhiro Narita and Masayoshi Sawaki and Keiichi Mikasa and Fumio Miki and Rinzo Soejima and Niro Okimoto and Takao Sasaki and Yukio Matsumoto and Yuji Sugimoto and Michio Yamakido and Shinichi Ishioka and Yoshiro Sawae and Yukio Kumagai and Kohei Hara and Keizo Matsumoto and Hirofumi Tanaka and Atsushi Shinoda and Yoshinari Kitahara and Atsushi Saito and Yoshiteru Shigeno and Yuei Irabu and Hiroshi Fukuhara and Masakiyo Ishihara and Koichi Deguchi and Nobuya Ogawa and Jingoro Shimada",

year = "1991",

doi = "10.11250/chemotherapy1953.39.844",

language = "English",

volume = "39",

pages = "844--863",

journal = "CHEMOTHERAPY",

issn = "0009-3165",

number = "9",

}

TY - JOUR

T1 - Double blind comparative study on cefetamet pivoxil vs cefixime in chronic respiratory tract infections

AU - Matsumoto, Fumio

AU - Imai, Takeo

AU - Saito, Akira

AU - Hiraga, Yohmei

AU - Ohmichi, Mitsuhide

AU - Takebe, Kazuo

AU - Imamura, Kenichi

AU - Oizumi, Kotaro

AU - Watanabe, Akira

AU - Nakai, Hiroyuki

AU - Saito, Junichi

AU - Niizuma, Kazunao

AU - Ohnuma, Kikuo

AU - Katsu, Masataka

AU - Ohishi, Akira

AU - Okui, Shinji

AU - Irimajiri, Shoichiro

AU - Matsuoka, Yasuo

AU - Mita, Seiji

AU - Sakai, Osamu

AU - Shimada, Jingoro

AU - Shiba, Kohya

AU - Tanimoto, Shinichi

AU - Ohara, Kazuo

AU - Ikemoto, Hideo

AU - Mori, Takeshi

AU - Ebe, Tsukasa

AU - Kobayashi, Hiroyuki

AU - Takeda, Hiroaki

AU - Oshitani, Hiroshi

AU - Hayashi, Izumi

AU - Nakata, Koichiro

AU - Noguchi, Masayuki

AU - Koyama, Masaru

AU - Shishido, Harumi

AU - Nagai, Hideaki

AU - Odagiri, Shigeki

AU - Suzuki, Kaneo

AU - Takahashi, Hiroshi

AU - Takahashi, Kenichi

AU - Arakawa, Masaaki

AU - Wada, Koichi

AU - Kawashima, Takashi

AU - Yamamoto, Toshiyuki

AU - Suzuki, Kanzo

AU - Matsuura, Toru

AU - Narita, Nobuhiro

AU - Sawaki, Masayoshi

AU - Mikasa, Keiichi

AU - Miki, Fumio

AU - Soejima, Rinzo

AU - Okimoto, Niro

AU - Sasaki, Takao

AU - Matsumoto, Yukio

AU - Sugimoto, Yuji

AU - Yamakido, Michio

AU - Ishioka, Shinichi

AU - Sawae, Yoshiro

AU - Kumagai, Yukio

AU - Hara, Kohei

AU - Matsumoto, Keizo

AU - Tanaka, Hirofumi

AU - Shinoda, Atsushi

AU - Kitahara, Yoshinari

AU - Saito, Atsushi

AU - Shigeno, Yoshiteru

AU - Irabu, Yuei

AU - Fukuhara, Hiroshi

AU - Ishihara, Masakiyo

AU - Deguchi, Koichi

AU - Ogawa, Nobuya

AU - Shimada, Jingoro

PY - 1991

Y1 - 1991

N2 - We carried out a double-blind comparative study on cefetamet pivoxil (CEMT-PI) to evaluate its clinical efficacy and safety in the treatment of bacterial respiratory tract infections (RTI) namely, infectious exacerbation of chronic respiratory disease, using cefixime (CFIX) as the active reference drug. Either CEMT-PI at 1,000 mg/day or CFIX at 400 mg/day was given orally in two divided doses for 14 days in principle. The results obtained were as follows. (1) The efficacy rates were 83.3 % (55/66) in the CEMT-PI group and 72.7 % (48/66) in the CFIX group as judged by the committee, and 81.8% (54/66) in the CEMT-PI group, and 69.7% (46/66) in the CFIX group as judged by the doctor in charge. No significant differences were observed in efficacy rates between the two treatment groups. (2) The rates of eradication of the causative organisms were 82.4 % (28/34) in the CEMT-PI group and 71.9 % (23/32) in the CFIX group as judged by the committee, with no significant difference between the two treatment groups. (3) The incidence of side effects was 9.3 % (7/75) in the CEMT-PI group and 3.9 % (3/77) in the CFIX group, and that of abnormal laboratory findings was 15.1 % (11/73) in the CEMT-PI group and 14.7% (11/75) in the CFIX group as judged by the committee. No significant differences were observed in the incidences of side effects and of abnormal laboratory findings. From our results we conclude that CEMT-PI is highly effective and useful in the treatment of bacterial respiratory tract infections and is equivalent to CFIX.

AB - We carried out a double-blind comparative study on cefetamet pivoxil (CEMT-PI) to evaluate its clinical efficacy and safety in the treatment of bacterial respiratory tract infections (RTI) namely, infectious exacerbation of chronic respiratory disease, using cefixime (CFIX) as the active reference drug. Either CEMT-PI at 1,000 mg/day or CFIX at 400 mg/day was given orally in two divided doses for 14 days in principle. The results obtained were as follows. (1) The efficacy rates were 83.3 % (55/66) in the CEMT-PI group and 72.7 % (48/66) in the CFIX group as judged by the committee, and 81.8% (54/66) in the CEMT-PI group, and 69.7% (46/66) in the CFIX group as judged by the doctor in charge. No significant differences were observed in efficacy rates between the two treatment groups. (2) The rates of eradication of the causative organisms were 82.4 % (28/34) in the CEMT-PI group and 71.9 % (23/32) in the CFIX group as judged by the committee, with no significant difference between the two treatment groups. (3) The incidence of side effects was 9.3 % (7/75) in the CEMT-PI group and 3.9 % (3/77) in the CFIX group, and that of abnormal laboratory findings was 15.1 % (11/73) in the CEMT-PI group and 14.7% (11/75) in the CFIX group as judged by the committee. No significant differences were observed in the incidences of side effects and of abnormal laboratory findings. From our results we conclude that CEMT-PI is highly effective and useful in the treatment of bacterial respiratory tract infections and is equivalent to CFIX.

KW - cefetamet pivoxil

KW - cefixime

UR - http://www.scopus.com/inward/record.url?scp=0026000394&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026000394&partnerID=8YFLogxK

U2 - 10.11250/chemotherapy1953.39.844

DO - 10.11250/chemotherapy1953.39.844

M3 - Article

AN - SCOPUS:0026000394

SN - 0009-3165

VL - 39

SP - 844

EP - 863

JO - CHEMOTHERAPY

JF - CHEMOTHERAPY

IS - 9

ER -

Double blind comparative study on cefetamet pivoxil vs cefixime in chronic respiratory tract infections

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this